Literature DB >> 24512639

Long-acting injectable antipsychotics: shall the last be first?

Stephen M Stahl.   

Abstract

ISSUE: A paradigm shift is afoot in which the "last shall be first," namely, use of long-acting injectable (LAI) antipsychotics, rather than being reserved for use only at the last stages of schizophrenia, may be shifting to first-line treatment of early episodes of this illness.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24512639     DOI： 10.1017/S1092852913001016

Source DB:  PubMed          Journal:  CNS Spectr        ISSN： 1092-8529            Impact factor:   3.790


  22 in total

1.  Oral Antipsychotic Versus Long-Acting Injections Antipsychotic in Schizophrenia Spectrum Disorder: a Mirror Analysis in a Real-World Clinical Setting.

Authors:  Nicola Poloni; Marta Ielmini; Ivano Caselli; Giulia Lucca; Alessandra Gasparini; Alessandra Gasparini; Giorgia Lorenzoli; Camilla Callegari
Journal:  Psychopharmacol Bull       Date:  2019-06-20

Review 2.  The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.

Authors:  Marc De Hert; Jan Sermon; Paul Geerts; Kristof Vansteelandt; Joseph Peuskens; Johan Detraux
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

Review 3.  Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia.

Authors:  Eduard Parellada; Miquel Bioque
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

Review 4.  Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability - a review.

Authors:  Alexandre González-Rodríguez; Rosa Catalán; Rafael Penadés; Clemente Garcia-Rizo; Miquel Bioque; Eduard Parellada; Miquel Bernardo
Journal:  Patient Prefer Adherence       Date:  2015-05-25       Impact factor: 2.711

Review 5.  Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia.

Authors:  Bernardo Carpiniello; Federica Pinna
Journal:  Drug Des Devel Ther       Date:  2016-05-24       Impact factor: 4.162

Review 6.  Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.

Authors:  Georgia L Stevens; Gail Dawson; Jacqueline Zummo
Journal:  Early Interv Psychiatry       Date:  2015-09-25       Impact factor: 2.732

Review 7.  Long-Acting Injectable Antipsychotics: A Systematic Review of Their Non-Systemic Adverse Effect Profile.

Authors:  Monica Zolezzi; Rawan Abouelhassan; Yassin Eltorki; Peter M Haddad; Mahtab Noorizadeh
Journal:  Neuropsychiatr Dis Treat       Date:  2021-06-14       Impact factor: 2.570

8.  Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate.

Authors:  Katy Mason; Joshua Barnett; Sofia Pappa
Journal:  Ther Adv Psychopharmacol       Date:  2021-07-20

9.  A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project.

Authors:  Miquel Bioque; Adrián Llerena; Bibiana Cabrera; Gisela Mezquida; Antonio Lobo; Ana González-Pinto; Covadonga M Díaz-Caneja; Iluminada Corripio; Eduardo J Aguilar; Antoni Bulbena; Josefina Castro-Fornieles; Eduard Vieta; Amàlia Lafuente; Sergi Mas; Mara Parellada; Jerónimo Saiz-Ruiz; Manuel J Cuesta; Miguel Bernardo
Journal:  Int J Neuropsychopharmacol       Date:  2016-03-31       Impact factor: 5.176

10.  Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate.

Authors:  Pedro Such; José Manuel Olivares; Lizbeth Arias; Mette Troels Berg; Jessica Madera
Journal:  Neuropsychiatr Dis Treat       Date:  2021-06-10       Impact factor: 2.570
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.